Indian govt bans Saridon, 327 other combination drugs

Indian govt bans Saridon, 327 other combination drugs

7:14 AM, 14th September 2018
Saridon
Popular drugs like the painkiller Saridon, the skin cream Panderm are banned. (File photo)

NEW DELHI, INDIA: The health ministry of India has, with immediate effect, put a ban on manufacture, sale, and distribution of 328 fixed-dose combinations (FDCs) of drugs and restricted another six. This marks an end of the legal battle between the ministry and the manufacturers of these drugs. The ministry has been working since 2016 to ban these “irrational” and “unsafe” drugs.

Among the roughly 6,000 brands estimated to be affected by the ban are popular drugs like the painkiller Saridon, the skin cream Panderm, combination diabetes drug Gluconorm, antibiotic Lupidicl, x and antibacterial Taxim AZ.

The government had banned 344 FDCs on March 10, 2016, and later added five more to this list. However, manufacturers of these drugs contested the ban in various high courts and the Supreme Court. The SC on December 15, 2017, asked for the matter to be examined by the Drugs Technical Advisory Board. DTAB concluded in its report that there was no therapeutic justification for the ingredients in 328 FDCs and that these could be a risk to people. The board recommended banning them.

In the case of six other FDCs, the board recommended restricted manufacture and sale subject to certain conditions based on their therapeutic justification. The SC ruled that the government could not use the DTAB report to prohibit 15 of the 344 drugs in the original list as these have been manufactured in India since before 1988. This exception covered several popular cough syrups, painkillers and cold medication with sales amounting to over Rs 740 crore annually. However, the court told the ministry that it could still look into the safety of these 15 drugs by initiating a fresh investigation if it wanted to ban them.

The All India Drug Action Network, a civil society group working on safety and access to medicines which was one of the petitioners in the Supreme Court case, welcomed the ban and sought action from the government on the 15 excluded FDCs. “The banned FDCs account for about Rs 2,500 crore and represents only the tip of the iceberg. 

In our estimate, the market for unsafe, problematic FDCs in India is at least one-fourth of the total pharma market which is valued at Rs 1.3 trillion,” said AIDAN in a statement. It also sought a review of all FDCs in the market in the interest of patient safety as recommended by the Kokate Committee, constituted by the health ministry to examine FDCs.

Meanwhile, many large drug companies have claimed that over the last couple of years they have either phased out such drugs or changed the combination. The FDCs in question is less than 2%, they claim.

© Times of India

0 Comments

Login

Your Comments (Up to 2000 characters)
Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Related News


Chemists make historic fluorine discovery

TEXAS, US: A groundbreaking discovery by chemists at The University of Texas at San Antonio (UTSA) will have a significant impact on how pharmaceutica ...

Read more
BASF to increase Hexanediol capacity at Ludwigshafen site

LUDWIGSHAFEN, GERMANY: BASF SE plans to increase the production capacity of 1,6-Hexanediol (HDO) at its Ludwigshafen Verbund site by more than 50 perc ...

Read more
Scientists pioneer a new way to turn sunlight into fuel

CAMBRIDGE, UK: The quest to find new ways to harness solar power has taken a step forward after researchers successfully split water into hydrogen and ...

Read more
Honeywell acquires gas processing technology developer

DES PLAINES, US: Honeywell has acquired Ortloff Engineers Ltd, a privately held licensor and industry-leading developer of specialized technologies th ...

Read more
AkzoNobel unveils 2019 colour of the year: Spiced Honey

AMSTERDAM, NETHERLANDS: AkzoNobel NV has unveiled Spiced Honey as the colour of the year for 2019. The shade was selected following expert research in ...

Read more
LyondellBasell, Covestro starts circular steam project in Maasvlakte

ROTTERDAM, NETHERLANDS: LyondellBasell (LYB) and its joint venture partner Covestro has started a large investment project at their site in Maasvlakte ...

Read more
www.worldofchemicals.com uses cookies to ensure that we give you the best experience on our website. By using this site, you agree to our Privacy Policy and our Terms of Use. X